Will the US\5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent `value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective - Université Claude Bernard Lyon 1 Accéder directement au contenu
Article Dans Une Revue Expert Opinion on Biological Therapy Année : 2020

Will the US\5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent `value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective

Martin Connock
  • Fonction : Auteur
Peter Auguste
  • Fonction : Auteur
Claude Dussart

Dates et versions

hal-03368061 , version 1 (06-10-2021)

Identifiants

Citer

Martin Connock, Lazaros Andronis, Peter Auguste, Claude Dussart, Xavier Armoiry. Will the US\5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent `value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective. Expert Opinion on Biological Therapy, 2020, 20, pp.823-827. ⟨10.1080/14712598.2020.1772747⟩. ⟨hal-03368061⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More